New questions about lung cancer in ‘never-smokers’ As the number of people who smoke has gone down over the decades, those who never smoked have begun to make up a greater proportion of lung cancer ...

Ocular Therapeutix's current wet AMD treatment is dominated by anti-VEGF drugs, with EYLEA holding a 63% global market share ...

The Food and Drug Administration has refused to review an application from the biotech company Moderna to approve its ...

Experts say the FDA "moved the goalposts" on Moderna, creating "a destructive precedent that will undermine the future of ...

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday ...

This week, vaccine manufacturer Moderna revealed that Vinaya Prasad, the top vaccine regulator at the Food and Drug ...

PROFIT: The pharmaceutical company is expected to report a loss of $1.02 billion, or $2.54 a share, according to analysts polled by FactSet. That compares with a loss of $1.12 billion, or $2.91 a ...

Vinay Prasad, the Trump administration’s top vaccine regulator at the Food and Drug Administration, single-handedly decided to refuse to review Moderna’s mRNA flu vaccine, overruling agency scientists ...

By Mariam Sunny and Michael Erman Feb 11 (Reuters) - A U.S. Food and Drug Administration official on Wednesday defended the agency's surprise decision to not review Moderna's experimental flu vaccine ...

Moderna noted the FDA did not identify any specific safety concerns with the vaccine and that the rejection was inconsistent with previous feedback.

The flu vaccine is its first using mRNA technology for influenza.

The U.S. Food and Drug Administration is refusing to consider Moderna's application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday.